Entrada Therapeutics, Inc.
TRDA$479M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBOSTON183 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
TRDA News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
ENTR-601-44
Duchenne Muscular Dystrophy (DMD)
ENTR-601-45
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ENTR-601-44 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
ENTR-601-45 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply